We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
News

Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease

Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
News

Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bacteriophages are viruses that infect bacteria. They were isolated for the first time a century ago and discovered to be antibacterial agents. More recently, researchers linked a specific strain of bacteria, adherent and invasive Escherichia coli (AIEC), to Crohn’s disease1, a chronic IBD condition. To explore the possibility that bacteriophages could be used to combat AIEC in IBD patients, Ferring first collaborated with the University of Lille, University of Auvergne and DigestScience, a foundation dedicated to research on digestive diseases, to better understand AIEC. Then, together with the Institut Pasteur and Intralytix, Ferring developed a combination of bacteriophages specifically designed to target AIEC strains found in Crohn’s disease patients.

In the collaboration announced today, Intralytix will assist Ferring in formulating and manufacturing the bacteriophages for use in clinical trials, which are expected to begin as soon as 2016.

"Crohn’s disease is a painful and debilitating condition with limited treatment options," said Per Falk, Executive VP and Chief Scientific Officer at Ferring. "Our development program to bring relief to CD patients with our bacteriophage treatment directed against AIEC bacteria is ongoing."

Advertisement